| Title |
Safety of Human Papillomavirus Vaccines: An Updated Review
|
|---|---|
| Published in |
Drug Safety, December 2017
|
| DOI | 10.1007/s40264-017-0625-z |
| Pubmed ID | |
| Authors |
Anastasia Phillips, Cyra Patel, Alexis Pillsbury, Julia Brotherton, Kristine Macartney |
| Abstract |
Human papillomavirus (HPV) vaccines are now included in immunisation programmes in 71 countries. Unfortunately, uptake has been impacted in some countries by reduced confidence in the safety of the HPV vaccine. In 2013, we published an extensive review demonstrating a reassuring safety profile for bivalent (2vHPV) and quadrivalent (4vHPV) vaccines. A nonavalent (9vHPV) vaccine is now available and HPV immunisation programmes have been extended to males in 11 countries. The aim of this updated narrative review was to examine the evidence on HPV vaccine safety, focusing on the 9vHPV vaccine, special populations and adverse events of special interest (AESI). The previous searches were replicated to identify studies to August 2016, including additional search terms for AESI. We identified 109 studies, including 15 population-based studies in over 2.5 million vaccinated individuals across six countries. All vaccines demonstrated an acceptable safety profile; injection-site reactions were slightly more common for 9vHPV vaccine than for 4vHPV vaccine. There was no consistent evidence of an increased risk of any AESI, including demyelinating syndromes or neurological conditions such as complex regional pain or postural orthostatic tachycardia syndromes. The risk-benefit profile for HPV vaccines remains highly favourable. |
X Demographics
The data shown below were collected from the profiles of 223 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 41 | 18% |
| Ireland | 18 | 8% |
| United Kingdom | 10 | 4% |
| Japan | 8 | 4% |
| Spain | 7 | 3% |
| Australia | 7 | 3% |
| Netherlands | 3 | 1% |
| Kenya | 2 | <1% |
| Germany | 2 | <1% |
| Other | 13 | 6% |
| Unknown | 112 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 175 | 78% |
| Scientists | 28 | 13% |
| Practitioners (doctors, other healthcare professionals) | 18 | 8% |
| Science communicators (journalists, bloggers, editors) | 2 | <1% |
Mendeley readers
The data shown below were compiled from readership statistics for 129 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 129 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 20 | 16% |
| Student > Bachelor | 17 | 13% |
| Student > Master | 15 | 12% |
| Researcher | 14 | 11% |
| Other | 10 | 8% |
| Other | 16 | 12% |
| Unknown | 37 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 40 | 31% |
| Nursing and Health Professions | 10 | 8% |
| Biochemistry, Genetics and Molecular Biology | 9 | 7% |
| Agricultural and Biological Sciences | 7 | 5% |
| Immunology and Microbiology | 5 | 4% |
| Other | 14 | 11% |
| Unknown | 44 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 166. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 April 2024.
All research outputs
#250,847
of 25,800,372 outputs
Outputs from Drug Safety
#19
of 1,873 outputs
Outputs of similar age
#5,578
of 451,754 outputs
Outputs of similar age from Drug Safety
#2
of 21 outputs
Altmetric has tracked 25,800,372 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,873 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.8. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 451,754 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.